THE CAPITAL GAINS CLUB TOP PICK May 12th 2017
OUR TOP BIOTECH PICK: 3D SIGNATURES INC.
(TSXV:DXD and OTCQB: TDSGF)
Predicting the course of diseases and personalizing treatment for the individual patient
“If successful, this could represent a first-in-class blood test which would specifically identify clinically significant prostate cancer. Such a tool does not currently exist for prostate cancer patients” said Dr. Laurence Klotz, the Chairman of the Canadian Urology Research Consortium
Executive Summary: 3D Signatures is a personalized medicine company with a proprietary software platform based on the three-dimensional (3D) analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient.
Dr. Sabine Mai, is the founder and largest shareholder of the company and is an internationally known researcher who has more than one hundred publications related to research on Genomics and Genomic Instability. Most recently she has contributed to a library of patents related to her work on 3D Genomic Analysis. She is the recipient of several academic awards including the Braidwood Jackson Memorial Award; the Dr. Saul Highman Memorial Award; the Rh Award (Basic Science); the J&J Cognition Challenge (2013). She was recognized in 2015 as one of the Top 100: Canada’s Most Powerful Women.
Dr. Mai has been instrumental in the development of innovative 3D analysis of genomic instability, which will help in diagnosing more specifically and earlier several forms of cancer. This will allow physicians to personalize treatment and improve the quality of outcomes. During the course of more than twenty years of research she has contributed to a portfolio of patents protecting her discoveries. Her vision is to use her discoveries for the benefit of patients everywhere.
Jonathan Goodman, the CEO of Knight Therapeutics Inc. (over $1 billion market capitalization biotech company) is a key advisor to 3D Signatures. In addition, Knight Therapeutics invested in 3D Signatures and has signed definitive licensing and distribution agreements with the company.
One of the main reasons we like 3D Signatures and the stock is because of its proprietary technology that analyzes a specific part of an individual’s unique DNA (their telomeres) to determine how a disease will progress and if a patient will respond to treatment. This information enables clinicians to measure the appropriateness and effectiveness of different treatments for specific patients.
3D Signature’s technology has over 20 years of research and over $25 million in non-dilutive research & development funding.
No wonder the board and management own approximately 35% of the company!
This is not an early stage biotech company with an undeveloped drug or technology platform – this is a company with an innovative technology and a dedicated team that only makes millions of dollars and saves countless lives if they continue to develop the technology with a view to selling the company to a much larger biotechnology company. We believe the company is poised for exponential gains and we have never sold a share. As the company progresses through various trials and continues to enter into partnerships with other companies, we believe the stock will perform well and the company will attract analysts and large fund managers.
The best way to make large sums of money in a stock is being positioned in a take-over target and that is what we believe 3D Signatures is.
Why a big Pharmaceutical company would acquire 3D Signatures
There are approximately 10,000 new cases of Hodgkin lymphoma and an estimated 1,500 deaths in the United States and Canada each year. Physicians cannot today predict which patients will respond to standard chemotherapy and enter long-term remission or not respond and relapse, requiring alternative but more aggressive forms of therapy. THERE IS CURRENTLY NO TEST TO PREDICT WHETHER PATIENTS WILL RESPOND TO STANDARD CHEMOTHERAPY OR NOT.
Every year, there are over three million existing and new cases of prostate cancer in the United States and Canada. A large proportion of these patients are needlessly overtreated and/or subjected to surgery -- costing the health care payers billions of dollars annually and inflicting unnecessary treatment and complications on patients. There is a significant unmet need, at every stage of the disease, for accurate and minimally invasive risk assessment tools to allow clinicians to make better treatment decisions. 3D Signatures wants to arm physicians with the tools necessary to confidently personalize treatment decisions for each individual prostate cancer patient. NO SUCH TESTS CURRENTLY EXIST.
Based on published work by Dr. Mai and her collaborators regarding real-time ex vivo feedback on several new therapeutic candidates and inbound interest from a number of major pharmaceutical companies, 3D Signatures is activating a dedicated strategy to engage industry in discussions around partnership opportunities. 3D Signatures' technology has the potential to identify lead therapeutic candidates through drug screening, select specific patients for clinical trials, monitor patients during clinical trials and ultimately work with pharmaceutical companies on the approval of companion diagnostics for precision medicine. There is significant potential value to be realized by pharmaceuticals companies in the form of efficient identification of new drugs, targeted clinical trials, objective real-time feedback during clinical trials and expedited regulatory approval by way of companion diagnostics.
3D Signature’s plan over the course of 2017:
Validation and preliminary approval of its lead prognostic test for Hodgkin lymphoma;
Initiation of a major clinical trial for blood-based monitoring tests for prostate cancer;
Strategic engagement with pharmaceutical companies for development of companion diagnostics; and
Securing the right people and partners to elevate its business.
Dr. Sabine Mai: Founder and Major Shareholder
Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science, University of Manitoba.
Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at University of Manitoba.
She was recognized in 2015 as one of the Top 100: Canada’s Most Powerful Women.
Jason Flowerday: CEO and Director
over a decade of business development and marketing work for two of the world’s largest pharmaceutical companies, Germany’s Bayer AG and US-based Johnson and Johnson.
Jonathan Goodman: Business Advisor
CEO of Knight Therapeutics (investor and partner with 3D Signatures)
The co-founder, President and CEO of Paladin Labs Inc. which was acquired by Endo for $3.2 billion. Under his leadership, $1.50 invested in Paladin at its founding was worth $142 nineteen years later.
The Potential: 3D Signatures is in discussions with multiple pharmaceutical companies, with candidate compounds in all phases of clinical trials, about potentially incorporating 3D Signature’s three-dimensional telomere analysis and proprietary software into their trials. The company can offer these organizations significant insight into the efficacy of their compounds and possibly provide information on dose dependent response, as well as toxicity related to each compound.
On December 7, 2016, 3D Signatures presented the preliminary results of an important collaborative initiative between the company and the Institut Universitaire de Ariologie et de Pneumologie De Quebec (“IUCPQ”) exploring the possibility of identifying a biological marker to distinguish between two deadly forms of lung cancer, multiple synchronous lung adenocarcinoma (“AC”) and metastatic lung AC, which is a significant unmet clinical need in the management of patients with multiple lung lesions. In every blinded patient sample the company analyzed, 3D Signature’s technology was able to distinguish between the two respective types of deadly lung cancer. The acquisition of 3D telomere images and analysis was performed in the company's reference lab using the company’s proprietary software platform, TeloView™. A poster was presented at the International Association for the Study of Lung Cancer (“IASLC”) 17th World Conference on Lung Cancer (“WCLC”) which took place in Vienna, Austria from December 4 to December 7, 2016.
3D Signature’s technology has over 20 years of research and over $25 million in non-dilutive research & development funding.
No wonder the board and management own approximately 35% of the company!
The upside potential is huge and there are many catalysts to shoot the stock a lot higher. The company has laid out its business plan and if they continue to execute on time and on budget then we see our exit through a takeover. We hold shares in this company. Will you?
Enjoy the Gains,
Capital Gains Club
C. Sargent, Managing Editor
Copyright © 2017 Capital Gains Club, All rights reserved.
You opted in to receiving emails at www.capitalgainsclub.com Enjoy!
Our mailing address is:
Capital Gains Club
Vancouver, BC V6C1T2
Add us to your address book
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list
What is a good amount of money to invest in a deal?
For starters, only invest what you can afford to lose. Start small and make some money and then start using your gains as “House Money”. Don’t take big risks with your own money. Make some money then use those profits as you see fit.
Secondly, laws prohibit the Capital Gains Club from giving any personal investment advice. You should consult with your broker or investment advisor about any decisions related to your investments.
Please don’t ever read a stock alert of ours and construe it to mean that we are asking you to buy the stock. We share our analysis on a stock and encourage you to take a look as well. Unlike some other newsletters, we want everyone to succeed otherwise Capital Gains Club won’t survive in the long run.
The website, its owners, their affiliates, directors, officers, employees, consultants and agents are hereafter collectively referred to as “Capital Gains Club”, “we”, “our” or “us”.
The information and recommendations made available here (“Information”) by Capital Gains Club and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. By accessing the site and receiving this email, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email. We do not sell, trade, or otherwise transfer to outside parties your personally identifiable information. This does not include trusted third parties who assist us in operating our website, conducting our business, or servicing you, so long as those parties agree to keep this information confidential. We may also release your information when we believe release is appropriate to comply with the law, enforce our site policies, or protect ours or others rights, property, or safety. However, non-personally identifiable visitor information may be provided to other parties for marketing, advertising, or other uses.
If you decide to opt-in to our mailing list, you will receive emails that may include company news, updates, related product or service information, etc.
Note: If at any time you would like to unsubscribe from receiving future emails, we include detailed unsubscribe instructions at the bottom of each email.
Please use our site as a place to get ideas and information. Enjoy our news analysis and other information, but never make an investment decision off of anything we say. Do your own research and analysis before buying or selling securities. Only invest an amount you can afford to lose. The Capital Gains Club is not registered as an adviser under the securities legislation of any jurisdiction and provides the Information in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.
In no event will the Capital Gains Club and/or its affiliates, employees, consultants or directors be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. Nothing in this site shall constitute an offer or solicitation to anyone in any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation.
This is not an investment advisory, and should not be used to make investment decisions. Information from the Capital Gains Club is often opinionated and should be considered for information purposes only. The information about companies we profile may contain errors and therefore you should not make any investment decision based on what you read here. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. Read our emails and newsletters as a place to gather ideas and read about our perspective on stocks. Capital Gains Club bases its recommendations and forecasts on techniques, research, analysis and publicly available information believed to be reliable in the past and at the time of publication. However, the Capital Gains Club makes no warranty as to the completeness, accuracy or usefulness of the information presented. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of Capital Gains Club may have positions in the stocks discussed above and may trade in the stocks mentioned. Don’t consider buying or selling any stock without conducting your own due diligence. We do not act in the capacity of any of the following and you should not construe our activities as involving any of the following:
Providing investment advice;
Acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration;
Securities trading expert;
Financial planner or financial planning;
Providing stock recommendations;
Providing advice about buy and sell or hold recommendations as to specific securities; or
Offer or sale of securities or solicitation to purchase securities.
You should not interpret any of our publications as investment advice. If you are seeking investment advice you should consult with an registered investment adviser, registered stockbroker, or other financial professional of your choosing.
Whether we receive cash or securities compensation, we fully disclose the receipt or anticipated receipt of such compensation. We may buy and sell securities of the same security we are disseminating information for.
Our activities may involve actual conflicts of interest, since we may receive monetary or securities compensation in the very securities we are providing information on and shortly after we receive the monetary compensation we may disseminate information about the securities or after we receive the securities, we may sell the securities during the period in which we disseminate information about the securities.
Many of the securities we profile are considered penny stocks. Penny stocks inherently involve high risk and price volatility. You may lose your entire investment in any penny stock that you invest in. You should be acutely aware of the following information and risks inherent in any penny stock investment that you may make, including any issuer profiled on our websites or otherwise:
There is an inherent conflict of interest between our information dissemination services involving various issuers and our receipt of compensation from those same issuers; We may buy and sell securities in the securities that we provide information dissemination services, which may cause: a) significant volatility in the issuer’s stock; (b) price declines from our selling activities; (c) permit us to make substantial profits while we are disseminating profiles or information about the issuer, yet may result in a diminished value to the stock for investors;
Many penny stocks are thinly traded or have low trading volume, which may lead to difficulties in selling your securities and extreme price volatility; Many of the penny stocks we profile or provide information about are subject to intense competition, extreme regulatory oversight and inadequate financing to pursue their operational plan;
The issuer profiles and information we provide represent only a small or even infinitesimal amount of information regarding the issuer and is insufficient to formulate an investment decision; as such, that information should only be a starting point from which you conduct an in-depth investigation of the issuer from available public sources, such as www.sec.gov, www.sedar.com, www.tmxmoney.com, www.otcmarkets.com, yahoofinance.com, www.cnsx.ca, www.google.com and other available public sources as well as consulting with your financial professional, investment adviser, registered representative with a registered securities broker-dealer;
We urge you to conduct an in-depth investigation of the issuer from the above or other available sources, especially because we only present limited information, which is an insufficient basis to invest in any stock, yet alone a penny stock; accordingly, you should proceed with such investigation to determine, among other things, information pertaining to the issuer’s financial condition, operations, business model, and risks involved in the issuer’s business;
You should determine whether the issuer we profile or provide information about is a development or early stage company, which is subject to the risks of a development or early stage company in a similar such business, including difficulties in obtaining financing for operations and future growth;
You should conduct an investigation of the innumerable risks that are inherent or present in the business plan of almost any stock issuer; therefore, do not use our profiles or any information contained in our website or profiles as the sole determination of making an investment decision; We may only present positive information regarding an issuer; therefore, you should conduct an in-depth investigation of any possible negative factors regarding such issuer;
You should accept our information in an “as is” state; in other words, your use of the information is at your own risk and such information may change at anytime and it is not based upon any verification or due diligence of the statements made; The information we disseminate about issuers may contain forward looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, projections as indicated by such words as “expects”, “will”, “anticipates”, “estimates” (other than historical information); therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation into any such forward looking statements;
Forward looking statements are limited to the time period in which they are made and we do not undertake to update forward looking statements that may change at anytime; and We may make statements in our profiles that an issuer’s stock price has increased over a certain period of time since our publication of information about an issuer because such stock price reflects only an arbitrary period of time, it is of no predictive or analytical quality and you should not use any such information in your analysis of any such issuer.
A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in our e-mails/newsletters. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; competition; litigation; loss of key directors, officers or advisors; general economic, market or business conditions; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the applicable regulatory authorities. However, a company’s past performance does not guarantee future results.
Except where prohibited by applicable law, any controversy, claim or dispute arising out of or relating to these terms or your use of the Information will be referred to and governed by and construed in accordance with the laws of the Province of British Columbia, without reference to its rules governing the choice or conflict of laws. The parties hereto irrevocably attorn and submit to the exclusive jurisdiction of the courts of the Province of British Columbia, sitting in the city of Vancouver, with respect to any dispute between the parties.
You expressly understand and agree that in no event will Capital Gains Club, its directors, officers, employees, consultants, advisors or affiliates be liable for any damages whatsoever, including any direct, indirect, incidental, consequential, special or exemplary damages, and any damages for loss of profits, savings, goodwill or other intangible losses, regardless of whether Capital Gains Club has been advised of or could have foreseen the possibility of such damages, arising out of or in connection with the use, inability to use or performance of any of the information provided by Capital Gains Club.
Never base any decision off our website or emails.